Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More bad news for Prempro  

Executive Summary

Preliminary analysis from the Women's Health Initiative Memory Study evaluating the use of estrogen plus progestin on the development of dementia and mild cognitive impairment suggests negative results. "In contrast to previous work that suggested a beneficial effect on memory and cognition, the preliminary analyses of this arm of WHIMS suggest certain negative findings in a small percentage of the study participants," Wyeth said. An earlier National Institutes of Health-funded study found Wyeth's Premarin (conjugated estrogens) had no effect in the treatment of Alzheimer's disease (1"The Pink Sheet" Feb. 8, 2000, p. 8)...

You may also be interested in...



Premarin Alzheimer's Prevention Studies Urged; Treatment Trial Negative

A trial finding no effect for Premarin in the treatment of Alzheimer's does not rule out a role for estrogen replacement therapy in prevention of the disease, Wyeth-Ayerst and the study authors pointed out.

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel